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Abstract 
Background: Incorrect use of inhaler devices remains an obstacle for respiratory diseases 
management. We aimed to evaluate the frequency of inhaler technique errors; to determine the 
devices perceived as the easiest and favourite to use; to study the association of device type, 
demographics and patient preferences with inhaler technique (IT). 
Methods: Cross-sectional assessment of 301 adults, with asthma (194) or chronic pulmonary 
obstructive disease, undergoing treatment with Aerolizer®, Autohaler®, Breezehaler®, Diskus®, 
Handihaler®, MDI without spacer, Miat-haler®, Novolizer®, Respimat® and/or Turbohaler®. Patients 
completed self-assessment questionnaires and face-to-face interview, with demonstration of 
inhaler technique. The rate of wrong steps (number of wrong steps ÷ number of total steps; RWS) 
was the primary outcome. Adjusted odds ratio (aOR) (95% confidence intervals [CI]) for 
presenting ≥1 IT errors were computed. 
Results: From the 464 inhaler technique performances, the median RWS was 18%. Turbohaler® 
(21%) and Diskus® (19%) were chosen as easiest and Novolizer® (18%), Diskus® (18%), 
Turbohaler® (17%) as favourite for daily use. Females (aOR 2.68 [95% CI 1.55-4.65]; vs. males] and 
patients with >64 yr. (aOR 2.73 [95% CI 1.15-6.48]; vs <45 yr.) were more likely to perform IT 
errors; otherwise, no association was found, including with using the favourite device (aOR 1.43 
[95% CI 0.84-2.42]). 
Conclusion: The frequency of inhaler technique errors was high and no device was clearly 
preferred over the others. Using the preferred inhaler device was not associated with less errors. 
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Introduction 
Inhaled therapy is the cornerstone in the management of asthma and chronic obstructive 
pulmonary disease (COPD). There are two main groups of inhaler devices: metered dose inhalers 
(MDI) and dry powder inhalers (DPI). Many devices have been developed and each has specificities 
on how to prepare the dose and deliver the drug to the airways. Although different devices have 
technological improvements to airway drug delivery, important limitations remain.1 In fact, decades 
after the introduction of inhaler devices, their incorrect use remains an obstacle to achieve 
optimal disease outcomes.2 
The correct use of inhaler devices is one of the most important aspects to be taken into 
account when evaluating individuals with asthma or COPD, and guidelines3, 4 emphasize the 
importance of assessing inhaler technique to improve the efficiency of drug delivery. Furthermore, 
it is recognized that inadequate use of inhaler devices is one of the most common reasons for 
failure to achieve asthma control.3 A recent review reports a high percentage of inhaler technique 
errors, but with great variability among studies.5 
To understand how to improve the use of inhalers, different aspects have been studied, 
such as types of devices;2, 6-9 patient factors (age, gender, education);2, 8, 10, 11 and patient 
preferences.7, 12 Yet, research results regarding the interaction between patient, device and 
technique are insufficient and inconsistent. 
The aims of this study are: 1) to evaluate the frequency of errors in the inhaler technique 
of asthma and COPD patients; 2) to determine which inhaler device is perceived as the easiest and 
which is considered the favourite for daily use; 3) to study the association of device type, 
demographic characteristics and patient preference variables with inhaler technique. 
 
Material and Methods 
Study design and participants 
This was a cross-sectional observational study, carried out in the Allergology and 
Pneumology outpatient clinics of the Centro Hospitalar São João, a tertiary university hospital in 
Porto, Portugal, from April to August 2013. Adult patients attending the outpatient clinics were 
invited to participate and were included if they had a medical diagnosis of asthma or COPD and 
were currently using an inhaler device. In this study, we assessed the most commonly used devices 
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from those available in Portugal: Aerolizer®, Autohaler®, Breezehaler®, Diskus®, Handihaler®, MDI 
without spacer, Miat-haler®, Novolizer®, Respimat® and Turbohaler®. Patients using different 
inhaler devices or those who were unable to read and/or write were excluded. 
This study was conducted according to the principles of the Helsinki Declaration. Written 
informed consent was obtained from all participants. The study procedures were approved by the 
Ethics Committee of Centro Hospitalar São João. We have followed STROBE recommendations 
for reporting observational studies.13 
Instruments and Data collection  
Data were collected using a structured written questionnaire (filled autonomously by the 
patient) and a face-to-face interview.  
First, the participant answered a questionnaire which evaluated the self-perception on 
his/her inhaler technique (“I perform correctly the technique of my inhaler”), satisfaction with the 
inhaler device, including comfort with public use (“I feel satisfied with my inhaler” and “I feel 
comfortable using my inhaler in public”) and the perception on how his/her preferences were 
taken into account at the time of inhaler‟s prescription (“I feel that my physician took into account 
my opinion and preferences when choosing my inhaler”). These questions were answered using 
Visual Analogic Scales (VAS), ranging from 0 (worst) to 100 (best) millimetres.  
On a second phase, each participant was asked to demonstrate the usual inhaler technique 
he/she followed with his/her current device(s), using a placebo inhaler. The inhaler technique for 
each device was evaluated using checklists based on the manufacturers‟ instructions available in the 
Portuguese drug agency database.14 Summarized lists of the recommended inhaler steps for each 
device are presented in Supplementary Tables 1, 2 and 3. The interviewer registered if each step 
was performed properly and in an adequate order.  
On a third phase, the interviewer explained the adequate inhaler technique for the 
participant‟s device(s) and demonstrated how to use the remainder inhalers. After the explanation 
and demonstration of use, each participant had the opportunity to test the available inhalers by 
him/herself.  
Finally, each participant was asked to elect the device perceived as the easiest and the one 
they would prefer for daily use; the reason(s) underlying the choice of the inhaler for daily use 
were inquired through an open question. 
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The study questionnaire was pre-tested in 12 patients in order to check for readability and 
ease of understanding. To ensure uniformity of the assessment, all interviews were performed by 
the same trained interviewer. In order to reduce possible confounding related to differences in the 
therapeutic effect of inhaled drugs available for each device, it was explicitly stated, during the 
interview, that all questions were related only to the physical and functional aspects of the inhalers 
and not to the drug and/or its effects or safety. 
Statistical analysis 
The main outcome of this study was the rate of wrong steps (RWS), defined as number of 
inhaler technique wrong steps divided by the total number of recommended steps. We calculated 
the sample size based on the RWS. Considering a significance level of 0.05, we admitted a standard 
deviation for the RWS of 0.15, with a margin of error of 0.014. The sample size calculated for 
these parameters was 444 demonstrations of inhaler technique. Considering the same standard 
deviation of 0.15 for the RWS of each inhaler device, the inclusion of 40 demonstrations per 
device gives this study a power of 85% to detect a difference of 0.1 between the RWS of two 
different inhalers.  
Categorical variables were described using absolute frequencies and proportions with 95% 
confidence intervals (95% CI); comparisons were performed using the Pearson chi-square test. For 
statistical analysis, age was recoded in three groups (<45; 45 to 64; and >64 years old) and the 
level of education was categorized according to the Portuguese education system (1 to 4; 5 to 9; 
10 to 12; and >12 years of school education). Continuous variables were described using mean 
with standard deviation (SD) or median with interquartile range (IQR), as appropriate to the data 
distribution; comparisons were performed using non-parametric Mann-Whitney U and Kruskall-
Wallis tests, as adequate. The inhalers used by less than 5% of total patients were not analysed 
individually except in what refers to the patient‟s preferences. The associations between the RWS 
and both VAS score and duration of inhaler use were studied with Spearman correlation 
coefficients (r2). The level of significance was set at p<0.05. 
Univariate logistic regression models were developed using independent variables as risk 
factors for “presence of errors in the inhaler technique”. The univariate models considered all the 
available factors with a possible association with the inhaler technique, including patient 
characteristics (medical diagnosis, gender, age and school education), device features (type of 
device, time of use and number of different devices in use) and patient preferences regarding the 
devices that are considered the easiest and the favourite for daily use. Multivariate logistic 
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regression models were developed for the presence of errors in the inhaler technique. The factors 
with a p-value <0.250 in the univariate analysis were included in the initial multivariate model; the 
model was progressively adjusted considering its calibration (Hosmer-Lemeshow statistics), 
discriminative power (Area Under the Curve (AUC) from the Receiver Operating Curve (ROC)) 
and the adjusted p-value of each variable; a p>0.05 in the Hosmer-Lemeshow statistics was 
deemed necessary to consider that the model was calibrated. The final model included gender, age 
groups, years of school education and type of inhaler device; interactions (2x2) between different 
variables were tested but did not significantly improve the model and were not included. Results 
of both univariate and multivariate logistic regression models were presented as odds ratio (OR) 
with [95% confidence interval (95% CI)]. Statistical analysis was conducted using SPSS Statistics® 
version 21 for Windows (IBM SPSS, Chicago, IL, USA). 
 
Results 
Overall, 464 devices were being used by the 301 individuals included in the study. All the 
participants completed the study questionnaire and there was no missing data regarding individual 
questions.  
The characteristics of the participants and their currently used inhalers are presented in 
Table 1 and 2, respectively. Turbohaler® and Diskus® were the most widely used devices, 
accounting for 27% and 19%, respectively, of all inhalers; Autohaler®, Breezhaler®, Miat-haler®, 
Novolizer® and Respimat® represented less than 5% of the devices in current use. Individuals with 
asthma used more frequently Turbohaler® (corresponding to 34% of total inhalers used in asthma), 
while most patients with COPD reported to use Handihaler® and Diskus® (26% and 21% of total 
COPD devices, respectively). Duration of use was, on average, similar between devices (mean 
[±SD] 4-5 [±4-5] years) except for MDI, which had been in use for a longer period (9 [±10] 
years). High grades were reported in the self-evaluation of inhaler technique (median 94%, p25-
p75 74-94%) and satisfaction with the current device (median 87%, p25-p75 74-94%). Table 2 
summarizes these results to each device. The scores regarding patient‟s perceived involvement in 
the choice of the device(s) and public use of the inhalers were also high (median 75%, p25-p75 26-
96% and median 86%, p25-p75 48-97%, respectively). 
Figure 1 shows the percentage of flawless inhaler technique performances and the 
distribution of the RWS for the most widely used inhaler devices. The frequency of errors at each 
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recommended step, discriminated by device, is presented in the Supplementary Tables 1, 2 and 3 
available online. 
When considering the preference on the easiest inhaler device, 56% of patients chose their 
current inhaler, 10% chose devices used in the past and 34% elected an inhaler they had never 
used. When considering the favourite device for daily use, 40% of participants chose their current 
device, 9% a device used in the past and most (51%) preferred a device they had never used. 
Figure 2 shows the proportion of patients reporting each device as the preferred (considering 
both the easiest and the favourite for daily use). Table 3 describes the reasons underlying the 
choice of an inhaler for daily use. Physical characteristics of the device were the most frequently 
reported motives for choosing an inhaler as the favourite (table 3); characteristics such as the 
colour control window present in Novolizer® (which provides feedback to the patient) and the 
compact format of Breezehaler® were referred, respectively, by 70% and 48% of the participants 
who selected Novolizer® and Breezehaler®, as the most important reasons for their choices. 
Duration of use (p=0.253), perception of correct technique performance (p=0.106), 
satisfaction with the device (p=0.376), patient involvement by the physician (p=0.947) and comfort 
with the use of the device in public (p=0.607) did not significantly correlate with the RWS.  
Females (vs. males, p<0.001), older individuals (>64 vs. ≤64 years old; p<0.001) and those 
with lower level of education (1 to 4 years vs. >12 years; p=0.001) had a higher RWS. The 
diagnosis of asthma or COPD (p=0.643), the number of different inhalers used (p=0.067), 
currently using the device chosen as the easiest to use (p=0.292) and currently using the favourite 
device (p=0.092) had no statistically significant association with the RWS. 
Table 4 presents the odds ratio with 95% CI for inhaler technique with errors, based on 
the univariate and multivariate logistic regression analysis. Individuals who where not using their 
favourite device had no significant increase in the OR for the presence of at least one error in the 
inhalation technique (crude OR 1.43 [95% CI 0.84-2.42]; vs. already using the favourite device). 
 
Discussion 
In this cross-sectional observational study we observed a high RWS in inhaler technique 
and a corresponding low percentage of inhaler technique performances without errors. In 
multivariate analysis, females, elder patients and those using the Aerolizer® and Handihaler® 
devices had higher odds of performing errors. Other variables such as inhaler device factors (e.g.: 
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using more than one type of device), medical diagnosis, education and patient preferences, 
including using the preferred inhaler device, were not associated with correct inhaler technique. 
Finally, there was no consensus on the inhaler device to be considered as the „easiest‟ or as the 
„preferred for daily use‟. 
Our study comprehensively assessed factors that may affect performance of inhalation 
technique in asthma and COPD patients, using questionnaires and face-to-face interview, with 
demonstration of patient inhaler technique and demonstration to the patient of 10 different 
inhaler devices. Previously these factors have been described separately, such as type of inhaler 
device, disease, demographic characteristics and patient preferences. To our knowledge, this is the 
largest set of inhaler devices to be simultaneously assessed in a study. Nevertheless, this study has 
some limitations that should be considered. We could not compare all devices regarding the RWS, 
because some devices (Autohaler®, Breezehaler®, Miat-haler®, Novolizer®, Respimat®) were used 
infrequently. During the interviews we felt patients often had difficulties in separating previous 
experiences with medications from the devices that were used to deliver them, although it was 
explicitly said by the interviewer that only the physical and functional aspects of the device were 
being evaluated. Also, some participants might have not fully understood the VAS questions. 
Moreover, under or over reporting of inhaler technique errors due to interviewer bias can not be 
excluded, although using a single interviewer prevented inter-observer variability. Additionally, the 
study was conducted in a single healthcare institution and study design cannot exclude a selection 
bias; furthermore, illiterate individuals were excluded. This may render generalization of our 
results to other populations difficult.  
A critical limitation to all studies evaluating inhaler technique is the lack of consensus 
regarding the methodology to assess and value errors. Other studies used several different 
methods such as critical errors,2 essential steps,6, 8, 9 grading systems7 or error cut-offs.10-12, 15 We 
calculated a rate of wrong steps, without valuing any particular steps. This method may 
overestimate the prevalence of incorrect use of inhaler devices, since it considers all steps 
recommended by manufacturers as a potential source of error, but it reduces the subjectivity of 
grading the relevance of some errors over the others in the absence of solid knowledge on the 
importance of each error on the distribution of the drug into the airways. 
Inhaler technique assessment detected a high RWS across many of inhaler technique stages, 
which corresponded to low proportion of performances without mistakes. Despite the lower 
RWS in Turbohaler® and Diskus® comparing with other devices, no inhaler had an overall 
technique performance that surpassed all the others. Previous reports suggest that inhaler device 
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mishandling worsens the clinical outcome,2, 15, 16 and therefore our data is motive of concern. 
Despite the differences in the inhalation technique, the choice of the inhaler device should be 
based on a physician-patient agreement, considering patient preferences, skills, availability of the 
intended drug, cost and physician experience.1, 3, 4 An educational project on inhaler technique 
directed both to healthcare professionals and patients reported improved outcomes in asthma and 
COPD patients,17 underlining the role the effectiveness of educational interventions. Other 
interventions suggest that education should be provided in a continuous12 and interactive fashion.16 
Furthermore, evidence suggests that if the inhaler technique is performed correctly, similar 
outcomes can be achieved regardless of the type of inhaler device used by the patient.18  
All inhaler devices included in this study had similar average durations of use, with the 
exception of MDI that had been used for a longer period of time. Hashmi et al10 reported that 
there was no significant relationship between duration of inhaler use and the presence of errors in 
inhaler technique, which is in accordance with our data. Likewise, our results are in agreement 
with previous literature reporting that there is no difference in the performance of inhaler 
technique according to the number of inhaler devices in use.2, 8 However, some authors reported 
more misuse amongst patients with multiple types of devices.6, 9, 11  
A previous study by Melani et al2 reported no statistically significant differences in inhaler 
technique between asthma and COPD patients, after adjusting for inhaler device, age and level of 
instruction. Our data support this lack of association. Nevertheless, they are discrepant with the 
results from Khassawneh et al;6 in that study there is a report of higher odds of incorrect inhaler 
technique in COPD patients, after adjusting for age, gender and level of education, although the 
authors attribute the difference to older age and the presence of more comorbidities in COPD 
patients.  
When considering demographic variables, we observed a higher odds ratio of poor inhaler 
technique in the elderly, as observed in previous studies.2, 8 Moreover, our data suggests that 
females, when compared to males, present a greater odds of having incorrect inhaler technique. 
However, in what refers to gender, most of the published studies reported no differences in 
inhaler technique.2, 8, 10, 11 This disagreement may be due to methodological differences, such as 
restricted analysis to specific errors2, 8 or application of cut-offs to define correct technique.10, 11 
Nevertheless, it seems that female patients often have worse asthma control in spite of higher 
inhaled corticosteroid use19 and COPD females seem to have more limitation, more dyspnoea and 
higher consumption of respiratory medication.20 Inhaler technique may contribute to the different 
outcomes observed between genders, being an interesting factor to be elucidated in future studies.  
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An inverse relation between years of school education and incorrect inhaler technique was 
previously reported.2, 10 We observed a similar trend in multivariate logistic regression analysis, 
with individuals with 5 to 9 years of school education presenting the highest OR for incorrect 
technique; however, individuals with higher level of school education were not significantly 
different from those with 1 to 4 years of education. Fayas et al11 observed that knowledge on 
asthma and inhaler technique, but not the level of academic education, was associated with better 
inhalation techniques; in our study, no specific data on asthma knowledge was collected. 
Nevertheless, recently, the WHO Regional Office for Europe suggested school education as one 
of the many factors that influences health literacy;21 this WHO manuscript did not include data 
from Portugal. Still, our observation seems to imply that physicians should not fully rely on the 
level of education as a predictor of correctness of inhalation technique. 
Guidelines recommend considering patient‟s opinions and preferences regarding their 
inhaler device(s) and technique(s) when assessing inhalation technique.3 Press et al16 reported that 
patients over-estimate their inhaler technique. Our analysis supports these findings, since most 
patients were confident about the correctness of their inhaler technique performance and this 
self-perception was not significantly associated with a lower RWS. Additionally, we observed that 
higher satisfaction with the inhaler device, personal perspective of being engaged by the physician 
in the choice of the device and feeling comfortable to use inhaler devices in public had no 
significant influence on the performance of inhaler technique.  
To study patient preferences, we compared ten inhaler devices to determine which was 
considered the easiest and the preferred for routine use but we could not identify an inhaler 
clearly favoured over the others. Interestingly, however, preferences seem to be greatly influenced 
by the prescription experience of our patients, since 66% chose the easiest device and 49% the 
preferred for routine use among those currently or formerly used. 
When considering the motive(s) for choosing an inhaler device as the preferred for routine 
use, we observed that reasons and their relative representation varied across each device. This 
opposes a previous report on patient preferences that referred that ease of use was the leading 
reason underlying the patient‟s choice; nevertheless that study was not designed to assess 
motives.7 The widely distributed preferences relating inhaler devices along with the existence of 
diverging reasons for the choice, indicates that prescription should not be standardized and that 
each patient must be considered individually. 
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Lenney et al7 previously reported that prescribing the preferred device to the patient might 
improve inhaler technique. In that study, the authors recruited patients referred for inhaler 
assessment and evaluated inhaler technique for all the devices immediately after giving verbal 
instruction and demonstrating their use. In our study, data does not support an association 
between using the preferred inhaler device and the correctness of inhaler technique. However, we 
invited participants with different backgrounds of inhaler use from an outpatient clinic and inhaler 
technique was assessed prior to any demonstration from the interviewer, which represents a 
more reliable approach to a real-life clinical setting. 
In conclusion, incorrect inhaler technique is frequent, especially in older patients and 
female patients. No inhaler device had a significant lower rate of wrong steps or was clearly 
preferred by the majority of the patients. Our data suggests that prescribing the patient‟s 
preferred inhaler is not associated with a better inhalation technique. 
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Tables 
Table 1 – Participants diagnosis, demographics and number of different inhalers used (n=301). 
 
 
  
n %
Diagnosis
Asthma 194 64
COPD 107 36
Gender (females) 181 60
Age (mean, SD) 53 17
< 45 90 30
45-64 132 44
>64 79 26
School years
1-4 138 46
5-9 67 22
10-12 62 21
> 12 34 11
1 166 55
2 108 36
≥3 27 9
Number of current different
inhalers
All
301
15 
 
Table 2 – Devices used, perception of correct technique and satisfaction with current inhaler 
(n=464). 
 
Footnote: *Visual analogic scale, range 0-100(best). 
 
  
n % P50 (P25-P75) P50 (P25-P75)
Turbohaler 128 27 86 (74-97) 79 (74-97)
Diskus 90 19 95 (74-97) 90 (74-97)
Handihaler 77 17 96 (75-97) 93 (74-97)
Aerolizer 64 14 96 (75-97) 93 (75-97)
MDI 54 12 92 (74-97) 92 (74-97)
Respimat 18 4 97 (76-97) 95 (74-98)
Novolizer 12 3 78 (74-97) 74 (50-94)
Breezehaler 11 2 96 (85-98) 96 (78-97)
Miat-haler 8 2 59 (12-97) 62 (8-75)
Autohaler 2 <1 62 (49-74) 50 (49-50)
Devices
(n=464)
Frequency 
of use
Self-evaluation of 
correct technique*
Satisfaction with 
current device*
16 
 
Table 3 – Motives stated by participants for choosing a device as favourite for daily use, sorted by 
preference for daily use (see figure 2). 
 
Footnote: The reasons stated by the participants were grouped according to its general 
type: 'Practical' includes 'practical' and 'fast to use'; 'Physic Characterist.' includes 'colour control 
window' (only for Novolizer), 'small size', 'hygienic', 'dosage counter', 'design' and 'discretion'. 
 
  
n % n % n % n %
Novolizer 1 1 5 8 6 9 54 82
Diskus 14 21 19 29 25 38 8 12
Turbohaler 27 44 9 14 15 24 11 18
MDI 9 21 18 41 14 31 3 7
Autohaler 1 4 18 67 6 22 2 7
Breezehaler 2 7 6 21 5 17 16 55
Aerolizer 5 23 9 41 6 27 2 9
Handihaler 5 26 4 21 7 37 3 16
Respimat 2 10 4 21 7 37 6 32
Miat-haler 2 100
18% 26% 26% 30%
Accustomed 
to Easy Practical
Physic
Characterist.
17 
 
Table 4 – Odds ratio (OR) from univariate (crude) and multivariate (adjusted) logistic regression 
analysis for the presence of at least one error in the inhaler technique. 
 
Footnote: NI - Not included 
 
Diagnosis
Asthma 1.02 (0.62-1.66)
COPD Reference NI
Male Reference Reference
Female 2.01 (1.23-3.29) 2.68 (1.55-4.65)
<45 Reference Reference
45-64 2.18 (1.23-3.86) 2.29 (1.11-4.75)
>64 2.13 (1.12-4.06) 2.73 (1.15-6.48)
1-4 Reference Reference
5-9 1.80 (0.86-3.76) 3.11 (1.31-7.37)
10-12 0.75 (0.40-1.40) 1.27 (0.57-2.86)
> 12 0.58 (0.28-1.21) 0.87 (0.36-2.09)
1 Reference NI
>1 1.80 (1.10-2.94)
Inhaler device
Aerolizer 3.46 (1.27-9.42) 3.24 (1.13-9.32)
Diskus 1.36 (0.69-2.68) 1.51 (0.73-3.11)
Handihaler 3.47 (1.37-8.79) 3.71 (1.38-10.02)
MDI 1.47 (0.64-3.35) 1.07 (0.45-2.57)
Other 0.86 (0.40-1.82) 0.97 (0.43-2.18)
Turbohaler Reference Reference
Time of inhaler use (years)
<1 Reference NI
1 to 5 1.36 (0.73-2.53)
>5 1.28 (0.65-2.53)
Yes Reference NI
No 1.26 (0.77-2.08)
Yes Reference NI
No 1.43 (0.84-2.42)
Crude
OR (95% CI)
Adjusted
OR (95% CI)
Already using the favourite device
Number of diferent devices
School years
Gender
Age groups (years)
Already using the easiest device
18 
 
Figures 
Figure 1 – Percentage of participants with flawless inhaler technique performances (diamonds) 
and distribution of rate of wrong steps (boxes and whiskers). 
 
Footnote: Percentage of users with flawless inhaler technique performances is represented 
by the diamond symbol. Distribution of the rate of wrong steps (number of wrong steps ÷ total 
number of steps; RWS) for the more frequently used devices. Box represents 25-75 percentiles 
and rectangle box the median. Whiskers represent 5 and 95 percentiles. Pearson Chi-Square test 
was used to test for statistical significant differences in the percentage of flawless inhaler technique 
executions  and Mann-Whittney U test was performed to test for statistically significant 
differences in the RWS. * p=0.006 for Turbohaler vs Handihaler. ¥ p=0.011 for Turbohaler vs 
Aerolizer. † p=0.001 for Turbohaler vs Handihaler. ‡ p=0.020 for Turbohaler vs Aerolizer. # 
p=0.015 for Turbohaler vs MDI. § p=0.038 for Diskus vs Handihaler. 
 
  
19 
 
Figure 2 – Percentage of patients reporting each device as the preferred, considering the easiest 
(left panel) and the favourite for daily use (right panel) devices, n=301 patient. 
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Questionário 
 
Questionário Número:_______   Data:___/___/_____ 
 
Dados sociodemográficos: 
Sexo: ⃞ Feminino ⃞ Masculino 
Idade:____  
Escolaridade:___________________ 
 
Dados relativos à doença: 
 Diagnóstico:______________________________________________________________________ 
 
Número Inalador Tempo de Utilização Actual 
   ⃞ 
   ⃞ 
   ⃞ 
   ⃞ 
   ⃞ 
 
 
 
Inquérito 1 
As seguintes perguntas pretendem saber a sua opinião relativamente à parte prática da utilização do seu 
inalador (se a técnica é fácil ou difícil) e ao seu aspecto físico (como, por exemplo, a forma ou o tamanho). 
Nenhuma pergunta se refere ao efeito que o medicamento (que se encontra dentro do inalador) tem nos 
seus pulmões e o que sente após a sua utilização. 
 
   Uso correctamente a técnica do meu inalador: 
Inalador:_______ 
 
 
Sinto-me satisfeito com o meu inalador: 
 
 
 
 
 Uso correctamente a técnica do meu inalador: 
Inalador:_______ 
 
 
Sinto-me satisfeito com o meu inalador: 
 
 
 
Totalmente 
Incorrecto 
Totalmente 
Correcto 
Totalmente 
Insatisfeito 
Totalmente 
Satisfeito 
Totalmente 
Incorrecto 
Totalmente 
Correcto 
Totalmente 
Insatisfeito 
Totalmente 
Satisfeito 
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Questionário Número:_______   Data:___/___/_____ 
 
 Uso correctamente a técnica do meu inalador: 
Inalador:_______ 
 
 
Sinto-me satisfeito com o meu inalador: 
 
 
 
 
Inquérito 2 
 Senti que o médico teve em conta a minha opinião e preferências na escolha do meu inalador: 
 
 
 
 
Sinto-me confortável em usar o meu inalador em público: 
 
 
 
Pós Intervenção: 
De todos os inaladores observados: 
 Mais fácil de usar no dia a dia:________________________________________________________ 
 Caso pudesse tomar a medicação em qualquer dispositivo, qual escolheria:____________________ 
o Motivos:____________________________________________________________________ 
Não teve nada 
em conta 
Teve tudo 
em conta 
Completamente 
à vontade 
Nunca usaria em 
público 
Totalmente 
Incorrecto 
Totalmente 
Correcto 
Totalmente 
Insatisfeito 
Totalmente 
Satisfeito 
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